Home › Therapeutic areas › Cardiovascular

Cardiovascular (23 companies · 23 conditions)

Conditions

Companies

Ticker Company Therapeutic areas In Cardiovascular Lead stage Mkt cap Programs
BIOA BioAge Labs CardiovascularOphthalmology 1 Phase 2 $234M 2
CRDL Cardiol Therapeutics Cardiovascular Rare 4 Phase 3 $124M 4
EWTX Edgewise Therapeutics Cardiovascular 3 Phase 2 $4.60B 3
EXEL Exelixis CardiovascularOncology 1 Approved $16.7B 23
GOSS Gossamer Bio Cardiovascular Rare 4 NDA Submitted $67.5M 4
INSM Insmed CardiovascularImmunology+3 Rare 2 Approved $26.7B 15
NTLA Intellia Therapeutics CardiovascularImmunology Rare 2 NDA Submitted $1.37B 3
IONS Ionis Pharmaceuticals CardiovascularHematology+5 Rare 5 Approved $4.49B 29
LXEO Lexeo Therapeutics CardiovascularNeurology Rare 3 Phase 2 $236M 12
LQDA Liquidia CardiovascularImmunology+1 Rare 5 Approved $5.11B 9
LGVN Longeveron CardiovascularNeurology Rare 2 Phase 2 $7.1M 3
MESO Mesoblast CardiovascularGI/Hepatology+2 Rare 1 Approved $1.54B 5
MIST Milestone Pharmaceuticals Cardiovascular 2 Approved $51.4M 2
MLYS Mineralys Therapeutics CardiovascularRenal+1 1 NDA Submitted $1.28B 3
GLUE Monte Rosa Therapeutics CardiovascularDermatology+3 Rare 1 Phase 2 $775M 7
NAMS NewAmsterdam Pharma CardiovascularMetabolic+1 3 NDA Submitted $2.33B 6
RVPH Reviva Pharmaceuticals CardiovascularDermatology+3 Rare 1 Phase 3 $4.7M 11
RCKT Rocket Pharmaceuticals CardiovascularImmunology Rare 3 Approved $236M 4
SLDB Solid Biosciences CardiovascularNeurology Rare 4 Phase 3 $695M 6
TECX Tectonic Therapeutic Cardiovascular Rare 4 Phase 2 $401M 4
TENX Tenax Therapeutics Cardiovascular Rare 2 Phase 3 $64.7M 2
RARE Ultragenyx Pharmaceutical CardiovascularMetabolic+1 Rare 1 Approved $1.70B 10
VNDA Vanda Pharmaceuticals CardiovascularDermatology+6 Rare 1 Approved $230M 27